Related Experiment Videos
Intermediate use of triazolam: a sleep laboratory study
The Journal of International Medical Research
|January 1, 1976
Summary
Triazolam (0.5 mg) effectively helps insomnia patients fall asleep and stay asleep. This sleep medication showed no significant negative impacts on sleep patterns or patient well-being over two weeks.
Area of Science:
- Pharmacology
- Sleep Medicine
- Clinical Psychology
Background:
- Insomnia is a prevalent sleep disorder affecting millions globally.
- Effective pharmacological interventions are crucial for managing insomnia.
- Triazolam is a benzodiazepine hypnotic used for short-term insomnia treatment.
Purpose of the Study:
- To assess the intermediate effects of triazolam (0.5 mg) on sleep in patients with insomnia.
- To evaluate triazolam's impact on sleep induction, maintenance, and sleep architecture.
- To determine the safety and tolerability of triazolam in this patient population.
Main Methods:
- A study involving insomniac patients receiving triazolam 0.5 mg.
- Evaluation of sleep parameters including induction and maintenance.
- Assessment of sleep staging and subjective patient reports.
- Monitoring of physical condition and effectiveness over a two-week period.
Main Results:
- Triazolam effectively induced and maintained sleep in insomniac patients.
- No significant alterations in sleep staging were observed.
- Patients reported no major subjective complaints or physical deterioration.
- Consistent effectiveness of triazolam was noted throughout the two-week study duration.
Conclusions:
- Triazolam (0.5 mg) is an effective and well-tolerated short-term treatment for insomnia.
- The medication aids in sleep initiation and continuity without disrupting normal sleep patterns.
- No adverse effects on patient well-being or physical health were identified during the study period.